Search
forProducts matching "hair pattern"
Tracking 44 products like 278 Mane Regain - RU58841 5% Solution, 14 Topical Finasteride & Minoxidil Spray, 15 Minoxidil Foam, 16 Oral Finasteride and 18 Finasteride+Minoxidil+supplement Blend from by companies like Amazon and Hims. View all 44 products »
Sort by
Research
840-870 / 1000+ resultsresearch Characteristics of Hypertrichosis Induced by 24-week Low-dose (5 mg Daily) Oral Minoxidil in Male Pattern Hair Loss Treatment
Low-dose oral minoxidil often causes excess hair growth but doesn't significantly affect quality of life.
research Exploring the impact of ovariectomy on hair growth: can ovariectomized mouse serve as a model for investigating female pattern hair loss in humans?
research Reply to: “Comment on: Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients”
research From consultation to compliance: factors affecting adherence to treatment for female pattern hair loss
research A Guide for Studying Spatiotemporal Variability in Murine Hair Cycle and Hair Growth Wave Patterns In Vivo
research Medical Pearl: Comparing crown part width to occipital part width to diagnose female pattern hair loss
research INDIVIDUAL ARTICLE: Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss
A clinical trial involving women, primarily of menopausal age, demonstrated that the dual cosmetic serum system by KilgourMD significantly improves female pattern hair loss. Over 4 months, the study used an objective combing test, a modified hair wash test, and clinical expert evaluations to measure the serum's effectiveness. The results showed statistically significant and clinically meaningful improvements, suggesting this serum system as a promising alternative treatment for hair loss in women, especially beyond the commonly used minoxidil.
research Correction to “Efficacy of Autologous Dermal Sheath Cup Cell Transplantation in Male and Female Pattern Hair Loss: A Single‐Arm, Multi‐Center, Phase III Equivalent Clinical Study”
research A Prospective Self-controlled Clinical Trial of Nonactivated Low Leukocyte PRP in Female Pattern Hair Loss Patients of Childbearing Age: Erratum
research A Prospective Self-controlled Clinical Trial of Nonactivated Low Leukocyte PRP in Female Pattern Hair Loss Patients of Childbearing Age: Erratum
research Commentary on: Clinical Use of Extracellular Vesicles in the Management of Male and Female Pattern Hair Loss: A Preliminary Retrospective Institutional Review Board Safety and Efficacy Study
research Faculty Opinions recommendation of Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial.
research 555 Doppler laser imaging predicts response to topical minoxidil in the treatment of female pattern hair loss
research Faculty Opinions recommendation of Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation.
research Faculty Opinions recommendation of Bead-jet printing enabled sparse mesenchymal stem cell patterning augments skeletal muscle and hair follicle regeneration.
research The role of the androgen receptor gene CAG repeat polymorphism and X-chromosome inactivation pattern in postmenopausal female pattern hair loss
research Substantial Sex-Dependent Differences in the Response of Human Scalp Hair Follicles to Estrogen Stimulation In Vitro Advocate Gender-Tailored Management of Female Versus Male Pattern Balding
research Androgenic Alopecia, Male and Female Pattern, Platelet Rich Plasma, Hair Pull Test.
research Retrospective analysis of the risk of hyperkalaemia in women older than 65 years of age prescribed spironolactone for female-pattern hair loss
research Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss
research Faculty Opinions recommendation of Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study.
research Efficacy, safety and tolerability of dutasteride in male patients with male pattern hair Loss
research Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Hair Loss, and Hirsutism
research Retinoic Acid and Mouse Skin Morphogenesis. I. Expression Pattern of Retinoic Acid Receptor Genes During Hair Vibrissa Follicle, Plantar, and Nasal Gland Development
research Finasteride, 1 mg (Propecia), Is the Optimal Dose for the Treatment of Men With Male Pattern Hair Loss
research Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
Finasteride and dutasteride are the most evidence-supported pharmacological treatments for androgenetic alopecia (AGA) in both men and women. Finasteride 1 mg/day reduces serum DHT by about 70%, while dutasteride 0.5 mg/day achieves approximately 90% suppression, with dutasteride showing slightly greater hair count gains. A pivotal trial found dutasteride 2.5 mg superior to finasteride 5 mg/day, but the 0.5 mg dose is standard due to its efficacy and lower systemic exposure. Genetic factors, particularly androgen receptor variations, significantly influence treatment response. In women, higher doses of finasteride and variable doses of dutasteride are effective, especially in postmenopausal and some premenopausal groups. The choice between these drugs involves balancing DHT suppression, drug half-life, and tolerability, with genetic modifiers being an important area for future research.
research Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
Finasteride and dutasteride are the most evidence-supported pharmacological treatments for androgenetic alopecia (AGA) in both men and women. Finasteride 1 mg/day reduces serum DHT by about 70%, while dutasteride 0.5 mg/day achieves approximately 90% suppression, with dutasteride showing slightly greater hair count gains. A pivotal trial found dutasteride 2.5 mg superior to finasteride 5 mg/day, but the 0.5 mg dose is standard due to its efficacy and lower systemic exposure. Genetic factors, particularly androgen receptor variations, significantly influence treatment response. In women, higher doses of finasteride and variable doses of dutasteride are effective, especially in postmenopausal and some premenopausal groups. The choice between these drugs involves balancing DHT suppression, drug half-life, and tolerability, with genetic modifiers being an important area for future research.
research Evaluation of the efficacy of topical spironolactone 5% solution versus minoxidil 5% solution vs combination of topical spironolactone 5% and minoxidil 5% solutions in female pattern hair loss
research Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation
Skin needs dermal β-catenin activity for hair growth and skin cell multiplication.